How should I manage breakthrough seizure-like activity with mouth and eyelid twitching in a patient already receiving levetiracetam (Keppra) and lorazepam (Ativan)?

Management of Breakthrough Seizure Activity in a Patient on Keppra and Ativan

For a patient already on levetiracetam (Keppra) and lorazepam (Ativan) experiencing breakthrough seizure-like activity with mouth and eyelid twitching, you should immediately administer an additional IV bolus of levetiracetam at 40 mg/kg (maximum 2,500 mg) on top of their maintenance dose, and if seizures persist, add IV valproate 20-30 mg/kg or phenobarbital 10-20 mg/kg as second-line therapy. 1

Initial Assessment and Stabilization

First, determine if this represents true status epilepticus (SE) versus focal motor seizures:

• Status epilepticus is defined as seizure activity lasting >5 minutes or recurrent seizures without return to baseline 1, 2
• Mouth and eyelid twitching could represent focal motor SE or non-convulsive SE
• Assess airway, breathing, circulation immediately
• Check blood glucose, electrolytes (sodium), and consider reversible causes (hypoglycemia, hyponatremia, hypoxia, drug toxicity, CNS infection) 1

Critical pitfall: Don't assume this is just "twitching" - focal motor seizures can progress to generalized convulsive SE and require aggressive treatment.

Pharmacologic Management Algorithm

Step 1: Optimize Benzodiazepine Dosing

Since the patient is already on Ativan (lorazepam), verify they received adequate dosing:

• Optimal dose: 0.1 mg/kg IV (maximum 4 mg per dose) 1, 2
• Can repeat after at least 1 minute (maximum 2 doses for convulsive SE) 3
• Important: Studies show that doses <4 mg are associated with 87% progression to refractory SE versus 62% with 4 mg doses 4

If inadequate benzodiazepine was given initially, administer proper dosing now before proceeding.

Step 2: Add Levetiracetam Bolus

The patient is already on maintenance Keppra, but breakthrough seizures require additional loading:

• Dose: 40 mg/kg IV bolus (maximum 2,500 mg) in addition to their maintenance dose 3
• Infuse at 5 mg/kg per minute 1
• This is supported by guidelines for breakthrough seizures in patients already on levetiracetam 3

Evidence strength: Multiple Class III studies show levetiracetam achieves 67-78% seizure control in benzodiazepine-refractory SE 1. The Neurocritical Care Society recommends levetiracetam as urgent second-line therapy 1.

Important caveat: A 2024 study found no difference in seizure termination between low-dose (≤20 mg/kg), medium-dose (21-39 mg/kg), and high-dose (≥40 mg/kg) levetiracetam, BUT the high-dose group had significantly higher intubation rates (45.8% vs 26.8-28.2%) 5. However, this study had limitations and guidelines still recommend 40 mg/kg for breakthrough seizures 3.

Step 3: If Seizures Persist After 10-20 Minutes

Add one of the following second-line agents:

Option A: IV Valproate (Preferred for most patients)

• Dose: 20-30 mg/kg IV at 40 mg/minute (maximum dose varies) 1
• Efficacy: 68-88% seizure control in refractory SE 1
• Advantages: No hypotension risk (unlike phenytoin), effective in both focal and generalized seizures 1
• Avoid in: Women of childbearing potential, hepatic dysfunction

Option B: Phenobarbital

• Dose: 10-20 mg/kg IV loading dose (maximum 1,000 mg) 3
• Maintenance: 1-3 mg/kg IV every 12 hours 3
• Efficacy: 58% as initial therapy in Class I study 1
• Disadvantages: Respiratory depression, sedation

Option C: Phenytoin/Fosphenytoin

• Dose: Phenytoin 18-20 mg/kg IV at 50 mg/minute 1
• Efficacy: Only 56% success rate, 84-88% when combined with valproate 1
• Disadvantages: Hypotension (12% vs 0% with valproate), cardiac arrhythmias, requires cardiac monitoring 1

Evidence Comparison

The 2014 ACEP guidelines 1 and 2024 update 2 provide the strongest evidence base. Key findings:

• Levetiracetam vs Valproate: Comparable efficacy (73% vs 68%) in refractory SE 1
• Levetiracetam vs Lorazepam: Equal effectiveness (76.3% vs 75.6%) with levetiracetam having less respiratory depression 6
• Combination therapy: Lorazepam + levetiracetam superior to other combinations in preventing refractory SE (10.5% vs 29.9%) 7

Special Considerations

If This is Non-Convulsive Status Epilepticus

Mouth and eyelid twitching without impaired consciousness suggests possible focal motor SE:

• Follow same algorithm but may not require immediate intubation
• Consider EEG monitoring if available 3
• Anesthetic agents (propofol, midazolam) generally NOT indicated for focal motor SE unless life-threatening 3

Maintenance Dosing After Seizure Control

Once seizures terminate:

• Lorazepam: 0.05 mg/kg (max 1 mg) IV every 8 hours for 3 doses 3
• Levetiracetam: Increase maintenance to 30 mg/kg IV every 12 hours OR increase prophylaxis dose by 10 mg/kg (to 20 mg/kg) every 12 hours (max 1,500 mg) 3
• Continue home antiepileptic regimen once able to take oral medications

When to Escalate to ICU/Anesthetic Agents

If seizures persist despite benzodiazepines + levetiracetam + second-line agent (refractory SE):

• Transfer to ICU immediately
• Consider continuous infusion of midazolam (2 mg/kg bolus, 5 mg/kg/hour infusion) or propofol (2 mg/kg bolus, 3-7 mg/kg/hour infusion) 1
• Propofol requires fewer ventilation days than pentobarbital (4 vs 14 days) 1
• Continuous EEG monitoring mandatory 3

Key Pitfalls to Avoid

1. Underdosing benzodiazepines: Doses <4 mg associated with 87% progression to refractory SE 4
2. Not adding levetiracetam bolus: Maintenance dosing alone is insufficient for breakthrough seizures
3. Delaying second-line therapy: Should be given within 10-20 minutes if seizures persist
4. Missing reversible causes: Always check glucose, sodium, and consider infection/toxicity
5. Using phenytoin first-line: Inferior efficacy and higher adverse effects compared to valproate or levetiracetam 1